A5040377013- Transplantation: Methods and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Polyomavirus and related diseases
- Hematopoietic Stem Cell Transplantation
- Mechanical Circulatory Support Devices
- Renal Transplantation Outcomes and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Viral Infections and Immunology Research
- Organ and Tissue Transplantation Research
- Respiratory viral infections research
- Organ Transplantation Techniques and Outcomes
- Pneumonia and Respiratory Infections
- RNA Interference and Gene Delivery
- Inhalation and Respiratory Drug Delivery
- Cystic Fibrosis Research Advances
Zambon (Germany)
2020-2023
Zambon (Italy)
2022
Bronchiolitis obliterans syndrome (BOS) is a major cause of morbidity and mortality in lung transplantation allogeneic hematopoietic stem cell (allo-HSCT) recipients. Clinical guidelines recommend function monitoring to aid early identification BOS, but real-world rates pulmonary testing (PFT) have not been studied. The purpose this study was quantify PFT allo-HSCT recipients.This longitudinal retrospective used US data from the IQVIA PharMetrics Plus commercial claims database (January 1,...
Chronic lung allograft dysfunction (CLAD), a common complication of transplantation, is the leading cause death for transplant recipients. While data on costs are available, impact CLAD healthcare resource use (HRU) and cost not well understood. The primary objective was to quantify HRU in US using real-world data.A longitudinal retrospective analysis performed commercial claims from IQVIA PharMetrics Plus database patients aged 18-64 who underwent transplantation between January 1, 2006...
Noninfectious pulmonary complications (NIPC) after allogeneic hematopoietic stem cell transplantation (alloHSCT), including bronchiolitis obliterans syndrome (BOS), cause significant morbidity and mortality, but their impact on health care resource utilization (HRU) costs is unknown. This longitudinal retrospective study quantified the economic burden of NIPC BOS in alloHSCT patients using commercial claims data from IQVIA PharMetrics Plus database. Study were aged 0 to 64 years underwent...
<b>Background:</b> The International Society of Heart and Lung Transplantation (ISHLT) reported data from 258 global lung transplant centers in 2016. Participation the ISHLT Registry is optional for non-US countries. Data submission to registry estimated represent approximately 80% worldwide thoracic activity (1). aim this review was characterize total annual number transplants Europe as by each country, correlate it with data. <b>Method:</b> As 2016 most recent year available data,...
RATIONALE: Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction, and major limitation long-term survival post transplantation (LTx).BOS affects up to 50% LTx recipients within 5 years post-transplant.Currently there are no therapies indicated specifically for BOS.The treatment augmentation systemic immunosuppression, which has limited efficacy associated with deleterious side effects.To address goal optimizing immunosuppression as a BOS, novel...